Sun Pharmaceutical Industries Ltd (SUNPHARMA)
🎯 Key Takeaways
- Sun Pharmaceutical Industries Ltd is in a strategic transition phase, shifting from mature growth to expansion-driven momentum fueled by innovation and a major acquisition. The company is leveraging strong domestic volume and innovative product performance to offset pressures in U.
- Revenue grew 4.7% QoQ to ₹15,300 in Q1FY27.
- ⚠️ U.S. generic market remains pressured by patent expiries and pricing erosion, as seen in the 9.7% YoY decline in U.S. sales, which could persist despi
📖 The Story
Sun Pharmaceutical Industries Ltd is in a strategic transition phase, shifting from mature growth to expansion-driven momentum fueled by innovation and a major acquisition. The company is leveraging strong domestic volume and innovative product performance to offset pressures in U.S. generics and emerging market headwinds, while advancing a transformative $11.75 billion acquisition to enter high-growth therapeutic areas like women's health and biosimilars.
📰 What's Happening
In Q1 FY27, Sun Pharma reported 10.1% YoY revenue growth to INR151,836 million, driven by 16% growth in India and 12.8% growth in innovative medicines (USD351 million). Despite a 9.7% decline in U.S. generic sales due to Lenalidomide patent expiry, adjusted net profit rose to INR30,894 million. The company secured semaglutide approvals in South Africa and Brazil, and reaffirmed full-year revenue growth guidance of high single digits. The Board approved the unaudited Q1 results and confirmed a definitive agreement to acquire Organon & Co. for $11.75 billion, with closing expected by Q4 FY27. Additionally, a shareholder postal ballot is underway to reclassify three related parties from the promoter group, reducing promoter holding to 52.68% and increasing public holding to 47.32%, without altering control.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Operating Profit | 3,601 | 3,798 | 4,216 | 3,179 | 3,679 |
| OPM % | 26.0% | 26.2% | 27.2% | 21.8% | 24.1% |
| Net Profit | 2,303 | 3,137 | 3,401 | 2,724 | 2,911 |
| EPS | ₹9.50 | ₹13.00 | ₹14.00 | ₹11.30 | ₹12.10 |
Revenue has shown consistent quarterly growth, rising from ₹13,851 crore in Jun 2025 to ₹15,300 crore in Jun 2026, with operating margins holding firm at 24-27% despite foreign exchange and commodity pressures. Profitability improved significantly, with net profit climbing from ₹2,303 crore (Jun 2025) to ₹2,911 crore (Jun 2026), and EPS increasing from ₹9.5 to ₹12.1 over the same period. This growth is underpinned by strong domestic volume and innovative product performance, as highlighted in management commentary, even as U.S. generic sales declined. The margin expansion reflects favorable product mix shifts and operational efficiency, supporting the outlook for sustained high single-digit growth despite macro headwinds.
🔮 Management Outlook & What's Next
Management expects full-year revenue growth in FY27 to be in the high single digits, supported by innovation-driven momentum and the Organon acquisition. They highlighted pipeline progress, including semaglutide approvals in emerging markets, and sustained R&D investment at 5.4% of sales. The integration of Organon is positioned as a strategic catalyst to expand into women's health and biosimilars, with tax benefits from deferred tax remeasurement and New Labour Code implementation contributing positively to margins. The company is focused on executing its acquisition with discipline, aiming for closure by Q4 FY27.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 240 | 240 | 240 | 240 |
| Reserves | 68,875 | 71,978 | 77,580 | 83,330 |
| Borrowings | 2,572 | 2,362 | 5,215 | 4,082 |
| Total Liabilities | 88,116 | 92,101 | 1.04 L Cr | 1.09 L Cr |
| Fixed Assets | 10,098 | 10,036 | 10,407 | 34,493 |
| Investments | 17,744 | 18,354 | 19,543 | 24,723 |
| Total Assets | 88,116 | 92,101 | 1.04 L Cr | 1.09 L Cr |
The balance sheet shows a deliberate shift in capital structure and capital allocation strategy. Equity remains stable at ₹240 crore, while reserves have grown from ₹71,978 crore (Mar 2025) to ₹83,330 crore (Mar 2026), reflecting retained earnings and accumulated profits. Borrowings have increased from ₹2,362 crore to ₹4,082 crore over the same period, indicating active financing for growth, likely tied to the Organon acquisition. Total assets have risen from ₹92,101 crore to ₹1.09 L crore, signaling expansion. This suggests management is prioritizing strategic investments over deleveraging, with a growing reliance on debt to fund transformational growth rather than returning capital.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +12,419 |
| Investing | -11,344 |
| Financing | -2,513 |
| Net Cash Flow | -1,437 |
👥 Shareholding Pattern
| Category | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% |
| FII | 18.0% | 18.1% | 18.0% | 17.3% | 16.6% | 16.1% | 15.9% | 14.5% |
| DII | 18.6% | 18.6% | 18.7% | 19.5% | 20.2% | 20.8% | 21.1% | 22.2% |
| Public | 5.4% | 5.5% | 5.4% | 5.3% | 5.5% | 5.4% | 5.3% | 5.5% |
| # Shareholders | 6,57,317 | 6,89,623 | 7,04,983 | 7,23,770 | 7,43,877 | 7,10,900 | 6,90,957 | 7,10,246 |
Promoter holding has remained stable at 54.48% over the last four quarters, but public shareholding has gradually increased from 5.3% to 5.48%, while FII and DII stakes have fluctuated slightly. FII holding rose from 15.93% (Q4FY26) to 14.53% (Q1FY27), and DII from 20.23% to 22.18%, indicating continued institutional confidence. The number of shareholders has declined slightly from 7.44 million to 7.10 million, suggesting consolidation. No significant promoter selling or large-scale institutional exit is evident, and the reclassification proposal aims to broaden the shareholder base without altering control.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.61 L Cr | 38.1 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.1 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.92 L Cr | 80.3 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.18 L Cr | 26.4 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.15 L Cr | 34.0 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.05 L Cr | 95.5 | 20.8% | 20.6% | 0.45 |
| LUPIN | 99,448 | 17.6 | 27.9% | 24.7% | 0.26 |
| MANKIND | 98,599 | 48.2 | 13.9% | 12.7% | 0.38 |
| DRREDDY | 98,308 | 30.4 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 94,937 | 25.8 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. U.S. generic market remains pressured by patent expiries and pricing erosion, as seen in the 9.7% YoY decline in U.S. sales, which could persist despite new launches. 2. Emerging market growth slowed to 4% in Q1 FY27, with forex volatility and macro uncertainty posing headwinds to revenue growth targets. 3. The $11.75 billion Organon acquisition carries integration and execution risks, including regulatory approvals, financing structure, and realization of synergies, with closing expected only by Q4 FY27. 4. Margin pressure could emerge if cost inflation or foreign exchange headwinds outpace pricing power, despite current gross margin expansion from product mix shifts.
📋 Recent Filings
-
Announcement 25 August 2026Sun Pharmaceutical announced its upcoming analyst and institutional investor meeting schedule on August 25, 2026, with the first session set for Septe...
-
🟡 Board Meeting 25 August 2026Sun Pharmaceutical Industries Limited announced a shareholder postal ballot to reclassify three related parties — Sudhir Valia, Raksha Valia, and Kris...
-
Announcement 17 August 2026Sun Pharmaceutical announced that the US Court of Appeals affirmed summary judgment in its favor regarding the Lipitor antitrust litigation, concludin...
-
🔴 Financial Results 6 August 2026Sun Pharmaceutical reported Q1 FY27 revenue of INR1,51,836 million, up 10.1% YoY, with net profit at INR28,948 million and adjusted net profit of INR3...
-
🟡 Board Meeting 31 July 2026Sun Pharmaceutical Industries Limited approved unaudited Q1 FY27 standalone and consolidated financial results for the quarter ended June 30, 2026, du...
-
🟡 Board Meeting 31 July 2026Sun Pharmaceutical Industries Limited announced that all resolutions proposed at its 34th Annual General Meeting held on 31 July 2026 were passed by s...
-
🟡 Board Meeting 31 July 2026Sun Pharmaceutical Industries Limited held its 34th Annual General Meeting on 31 July 2026 via video conference, where shareholders approved all propo...
-
Announcement 29 July 2026Sun Pharmaceutical Industries Limited announced that it has received approval from Brazil's ANVISA to manufacture and market semaglutide injection for...
-
Announcement 27 July 2026Sun Pharmaceutical announced that its partner Philogen resubmitted the Nidlegy™ Marketing Authorization Application to the EMA for neoadjuvant melanom...
-
Announcement 24 July 2026Sun Pharmaceutical announced that Organon shareholders approved the merger plan to make Organon a wholly owned subsidiary of Sun Pharma's US holding c...
🧠 Analyst's Read
Sun Pharma is transitioning from a volume-driven pharmaceutical player to a diversified, innovation-led global company, anchored by a major acquisition and strong domestic performance. The near-term trajectory hinges on successful integration of Organon and sustained momentum in innovative medicines, while navigating U.S. generic pressure and emerging market volatility. Investors should monitor the pace of the Organon closing, U.S. sales stabilization, and the impact of emerging market macro trends on growth guidance.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when SUNPHARMA files new disclosures
Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track SUNPHARMA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd